Liver Cirrhosis Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Gwo Xi Stem Cell Applied Technology Co., Ltd, Lipocine Inc, Calliditas Therapeutic

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Liver Cirrhosis pipeline constitutes 50+ key companies continuously working towards developing 50+ Liver Cirrhosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Liver Cirrhosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Liver Cirrhosis Market.

The Liver Cirrhosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Liver Cirrhosis Pipeline Report: https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Liver Cirrhosis treatment therapies with a considerable amount of success over the years.
• Liver Cirrhosis companies working in the treatment market are PharmaIN, Gwo Xi Stem Cell Applied Technology Co., Ltd, Lipocine Inc, Calliditas Therapeutics, Galectin Therapeutics, Zydus Therapeutics, Madrigal Pharmaceuticals, Inc., Galectin Therapeutics Inc., Grifols Therapeutics LLC, CymaBay Therapeutics, Akero Therapeutics, Inc., NGM Biopharmaceuticals, Inc.l, Gilead Sciences, Novo Nordisk A/S, Cellaion, Promethera Therapeutics, and others, are developing therapies for the Liver Cirrhosis treatment
• Emerging Liver Cirrhosis therapies in the different phases of clinical trials are- PHIN-214, GXHPC1, LPCN 1148, Setanaxib, Belapectin, Saroglitazar, Resmetirom (MGL-3196), Belapectin (GR-MD-02), Albutein, Seladelpar, Efruxifermin (AKR-001), Aldafermin (NGM282), Semaglutide, Cilofexor, and Firsocostat, NNC0194-0499, HepaStem, and others are expected to have a significant impact on the Liver Cirrhosis market in the coming years.
• In June 2023, The New England Journal of Medicine's online version reported that in NASH patients, a medicine that mimics a hormone in the body reduced liver inflammation and hepatic fibrosis, or scarring of the liver.
• In January 2023, In order to develop and market CymaBay Therapeutics' investigational medication eladelpar for the treatment of primary biliary cholangitis in Japan, the two companies have engaged into a collaboration and licence agreement

Liver Cirrhosis Overview
The histological growth of regenerating nodules encircled by fibrous bands in response to chronic liver injury, which causes portal hypertension and end-stage liver disease, is known as liver cirrhosis. The onset and development of liver fibrosis and cirrhosis are influenced by a wide variety of cells, cytokines, and miRNAs.

Get a Free Sample PDF Report to know more about Liver Cirrhosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Liver Cirrhosis Drugs Under Different Phases of Clinical Development Include:
• PHIN-214: PharmaIN
• GXHPC1: Gwo Xi Stem Cell Applied Technology Co., Ltd
• LPCN 1148: Lipocine Inc
• Setanaxib: Calliditas Therapeutics
• Belapectin: Galectin Therapeutics
• Saroglitazar: Zydus Therapeutics
• Resmetirom (MGL-3196): Madrigal Pharmaceuticals, Inc.
• Belapectin (GR-MD-02): Galectin Therapeutics Inc.
• Albutein: Grifols Therapeutics LLC
• Seladelpar: CymaBay Therapeutics
• Efruxifermin (AKR-001): Akero Therapeutics, Inc.
• Aldafermin (NGM282): NGM Biopharmaceuticals, Inc.
• Semaglutide, Cilofexor, and Firsocostat: Gilead Sciences/Novo Nordisk A/S
• Semaglutide, NNC0194-0499: Novo Nordisk A/S
• HepaStem: Cellaion/Promethera Therapeutics

Liver Cirrhosis Route of Administration
Liver Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Liver Cirrhosis Molecule Type
Liver Cirrhosis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Liver Cirrhosis Pipeline Therapeutics Assessment
• Liver Cirrhosis Assessment by Product Type
• Liver Cirrhosis By Stage and Product Type
• Liver Cirrhosis Assessment by Route of Administration
• Liver Cirrhosis By Stage and Route of Administration
• Liver Cirrhosis Assessment by Molecule Type
• Liver Cirrhosis by Stage and Molecule Type

DelveInsight's Liver Cirrhosis Report covers around 50+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Liver Cirrhosis product details are provided in the report. Download the Liver Cirrhosis pipeline report to learn more about the emerging Liver Cirrhosis therapies at:
https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Liver Cirrhosis Therapeutics Market include:
Key companies developing therapies for Liver Cirrhosis are - Madrigal Pharmaceuticals, Inc., Zydus Therapeutics Inc., PharmaIN, Rebiotix Inc., Grifols Therapeutics LLC, Exelixis, Vir Biotechnology, Inc., Lipocine Inc, Vedanta Biosciences, Inc., NGM Biopharmaceuticals, Inc, BioVie Inc., Ocelot Bio, Inc, Genfit, CymaBay Therapeutics, Inc., Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Akero Therapeutics, Inc, HighTide Biopharma Pty Ltd, Intercept Pharmaceuticals, Kowa Research Institute, Inc., COUR Pharmaceutical Development Company, Inc., and others.

Liver Cirrhosis Pipeline Analysis:
The Liver Cirrhosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Liver Cirrhosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cirrhosis Treatment.
• Liver Cirrhosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Liver Cirrhosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cirrhosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Liver Cirrhosis drugs and therapies-
https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Liver Cirrhosis Pipeline Market Drivers
• Increasing Prevalence for the treatment of Liver Cirrhosis, increase in the growing government initiatives and rising awareness are some of the important factors that are fueling the Liver Cirrhosis Market.

Liver Cirrhosis Pipeline Market Barriers
• However, side-effects associated with the treatment of Liver Cirrhosis, high cost associated with the treatment and other factors are creating obstacles in the Liver Cirrhosis Market growth.

Scope of Liver Cirrhosis Pipeline Drug Insight
• Coverage: Global
• Key Liver Cirrhosis Companies: PharmaIN, Gwo Xi Stem Cell Applied Technology Co., Ltd, Lipocine Inc, Calliditas Therapeutics, Galectin Therapeutics, Zydus Therapeutics, Madrigal Pharmaceuticals, Inc., Galectin Therapeutics Inc., Grifols Therapeutics LLC, CymaBay Therapeutics, Akero Therapeutics, Inc., NGM Biopharmaceuticals, Inc.l, Gilead Sciences, Novo Nordisk A/S, Cellaion, Promethera Therapeuticss, and others
• Key Liver Cirrhosis Therapies: PHIN-214, GXHPC1, LPCN 1148, Setanaxib, Belapectin, Saroglitazar, Resmetirom (MGL-3196), Belapectin (GR-MD-02), Albutein, Seladelpar, Efruxifermin (AKR-001), Aldafermin (NGM282), Semaglutide, Cilofexor, and Firsocostat, NNC0194-0499, HepaStem, and others
• Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and Liver Cirrhosis emerging therapies
• Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and Liver Cirrhosis market barriers

Request for Sample PDF Report for Liver Cirrhosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/liver-cirrhosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Liver Cirrhosis Report Introduction
2. Liver Cirrhosis Executive Summary
3. Liver Cirrhosis Overview
4. Liver Cirrhosis- Analytical Perspective In-depth Commercial Assessment
5. Liver Cirrhosis Pipeline Therapeutics
6. Liver Cirrhosis Late Stage Products (Phase II/III)
7. Liver Cirrhosis Mid Stage Products (Phase II)
8. Liver Cirrhosis Early Stage Products (Phase I)
9. Liver Cirrhosis Preclinical Stage Products
10. Liver Cirrhosis Therapeutics Assessment
11. Liver Cirrhosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Liver Cirrhosis Key Companies
14. Liver Cirrhosis Key Products
15. Liver Cirrhosis Unmet Needs
16 . Liver Cirrhosis Market Drivers and Barriers
17. Liver Cirrhosis Future Perspectives and Conclusion
18. Liver Cirrhosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Liver Cirrhosis Market https://www.delveinsight.com/report-store/liver-cirrhosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Liver Cirrhosis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Liver Cirrhosis Epidemiology https://www.delveinsight.com/report-store/liver-cirrhosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Liver Cirrhosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.